Treatment-emergent adverse events occurring in 20% or more of all treated patients
| Preferred term . | Total TEAEs,* n (%) . | TEAEs ≥ grade 3, n (%) . |
|---|---|---|
| Any event | 53 (100) | 52 (98) |
| Fatigue | 33 (62) | 8 (15) |
| Thrombocytopenia | 33 (62) | 30 (57) |
| Nausea | 28 (53) | 0 (0) |
| Anemia | 26 (49) | 24 (45) |
| Febrile neutropenia | 26 (49) | 26 (49) |
| Constipation | 25 (47) | 0 (0) |
| Decreased appetite | 24 (45) | 1 (2) |
| Neutropenia | 24 (45) | 22 (42) |
| Edema peripheral | 22 (42) | 0 (0) |
| Dyspnea | 18 (34) | 3 (6) |
| Pyrexia | 17 (32) | 2 (4) |
| Diarrhea | 15 (28) | 3 (6) |
| Dizziness | 15 (28) | 1 (2) |
| Vomiting | 15 (28) | 1 (2) |
| Hypotension | 13 (25) | 5 (9) |
| Cough | 12 (23) | 0 (0) |
| Headache | 11 (21) | 0 (0) |
| Insomnia | 11 (21) | 0 (0) |
| Preferred term . | Total TEAEs,* n (%) . | TEAEs ≥ grade 3, n (%) . |
|---|---|---|
| Any event | 53 (100) | 52 (98) |
| Fatigue | 33 (62) | 8 (15) |
| Thrombocytopenia | 33 (62) | 30 (57) |
| Nausea | 28 (53) | 0 (0) |
| Anemia | 26 (49) | 24 (45) |
| Febrile neutropenia | 26 (49) | 26 (49) |
| Constipation | 25 (47) | 0 (0) |
| Decreased appetite | 24 (45) | 1 (2) |
| Neutropenia | 24 (45) | 22 (42) |
| Edema peripheral | 22 (42) | 0 (0) |
| Dyspnea | 18 (34) | 3 (6) |
| Pyrexia | 17 (32) | 2 (4) |
| Diarrhea | 15 (28) | 3 (6) |
| Dizziness | 15 (28) | 1 (2) |
| Vomiting | 15 (28) | 1 (2) |
| Hypotension | 13 (25) | 5 (9) |
| Cough | 12 (23) | 0 (0) |
| Headache | 11 (21) | 0 (0) |
| Insomnia | 11 (21) | 0 (0) |
Only TEAEs with any grade prevalence of ≥ 20% are included.